Overview

• AxoGen Q3 revenue rises 23.5% yr/yr to $60.1 mln, beating analyst expectations

• Adjusted EPS for Q3 beats consensus

• Company reports net income of $0.7 mln, reversing a loss from last year

Outlook

• Company raises full-year revenue growth guidance to at least 19%, or $222.8 mln

• Company expects full-year gross margin between 73% and 75%

• FDA approval of Avance Nerve Graft BLA anticipated by December 5, 2025

Result Drivers

• BROAD-BASED GROWTH - Revenue growth was broad-based with double-digit increases across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast

• EXPANDED COVERAGE - Increased coverage and reimbursement for nerve repair procedures added 1.1 mln covered lives, enhancing market access

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for AxoGen Inc is $25.00, about 27.7% above its October 28 closing price of $18.08

• The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release: ID:nGNX9wHJK6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)